DiaSorin S.p.A. (BIT:DIA)
Italy · Delayed Price · Currency is EUR | Market Cap | 3.35B -37.5% |
| Revenue (ttm) | 1.17B -3.3% |
| Net Income | 141.62M -27.0% |
| EPS | 2.67 |
| Shares Out | 53.00M |
| PE Ratio | 23.65 |
| Forward PE | 15.62 |
| Dividend | 1.30 (2.06%) |
| Ex-Dividend Date | May 18, 2026 |
| Volume | 322,671 |
| Average Volume | 291,565 |
| Open | 64.24 |
| Previous Close | 64.24 |
| Day's Range | 63.04 - 65.14 |
| 52-Week Range | 52.34 - 97.56 |
| Beta | 0.66 |
| RSI | 55.10 |
| Earnings Date | May 7, 2026 |
About DiaSorin
DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, gastrointestinal diseases, hepatitis and retroviruses, endocrinology, metabolic disorders, tumor markers, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine... [Read more]
Financial Performance
In 2025, DiaSorin's revenue was 1.20 billion, an increase of 0.81% compared to the previous year's 1.19 billion. Earnings were 155.62 million, a decrease of -17.27%.
Financial StatementsNews
Q1 2026 DiaSorin SpA Earnings Call Transcript
Q1 2026 DiaSorin SpA Earnings Call Transcript
DiaSorin price target lowered to EUR 62 from EUR 65 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on DiaSorin (DSRLF) to EUR 62 from EUR 65 and keeps a Hold rating on the shares.
DiaSorin downgraded to Neutral from Buy at UBS
UBS analyst Kavya Deshpande downgraded DiaSorin (DSRLF) to Neutral from Buy with a price target of EUR 66, down from EUR 84. The firm sees modest risk to estimates and
DiaSorin price target lowered to EUR 65 from EUR 74 at Deutsche Bank
Deutsche Bank analyst Jan Koch lowered the firm’s price target on DiaSorin (DSRLF) to EUR 65 from EUR 74 and keeps a Hold rating on the shares. Published first on
DiaSorin price target lowered to EUR 60 from EUR 65 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on DiaSorin (DSRLF) to EUR 60 from EUR 65 and keeps an Equal Weight rating on the shares.
DiaSorin Earnings Call Transcript: Q4 2025
2025 saw modest revenue growth and strong immuno performance, offset by China headwinds and FX impacts. 2026 guidance is for 5%-6% revenue growth and 32%-33% EBITDA margin, with growth back-loaded due to weak H1 flu season and tough comps.
DiaSorin price target raised to EUR 74 from EUR 71 at Deutsche Bank
Deutsche Bank analyst Jan Koch raised the firm’s price target on DiaSorin (DSRLF) to EUR 74 from EUR 71 and keeps a Hold rating on the shares. Published first on
DiaSorin price target raised to EUR 65 from EUR 63 at Morgan Stanley
Morgan Stanley analyst Aisyah Noor raised the firm’s price target on DiaSorin (DSRLF) to EUR 65 from EUR 63 and keeps an Equal Weight rating on the shares. Published first
DiaSorin upgraded to Neutral from Underperform at BNP Paribas
BNP Paribas analyst Hugo Solvet upgraded DiaSorin (DSRLF) to Neutral from Underperform.
DiaSorin downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley downgraded DiaSorin (DSRLF) to Equal Weight from Overweight with a price target of EUR 63, down from EUR 99. The firm says macro headwinds continue to present earnings
DiaSorin price target lowered to EUR 58 from EUR 68 at JPMorgan
JPMorgan lowered the firm’s price target on DiaSorin (DSRLF) to EUR 58 from EUR 68 and keeps an Underweight rating on the shares.
DiaSorin Earnings Call Transcript: Q3 2025
Revenues grew 3% year-over-year to EUR 900 million, with core business up 6% at constant FX. Immuno and molecular segments showed solid growth outside China, while LTG faced life science headwinds. 2025 guidance was revised to 5% ex-COVID revenue growth and 33% EBITDA margin.
DiaSorin Earnings Call Transcript: Q2 2025
H1 2025 saw 5% revenue growth to EUR 619 million, with core business up 8% at constant FX and EBITDA margin at 35%. Immunodiagnostics and Molecular Diagnostics segments delivered strong growth, while China faced double-digit declines. 2025 guidance for 8% core revenue growth and 34% EBITDA margin is confirmed.
DiaSorin Earnings Call Transcript: Q1 2025
Q1 2025 saw 8% revenue growth and a 34% EBITDA margin, driven by strong immunodiagnostics and molecular segments, while COVID sales declined as expected. U.S. growth outpaced Europe, China remained challenging, and guidance for 2025 was confirmed.
Italy's DiaSorin ex-Covid revenue in line with guidance
Italian medical diagnostics group DiaSorin on Friday reported a 3% rise in 2024 revenue, citing dampened demand for its products with a milder Flu season compared to the previous year.
DiaSorin Earnings Call Transcript: Q4 2024
2024 saw solid revenue and margin growth, driven by strong U.S. and European immunoassay and molecular performance, with ex-COVID business up 7%. Guidance for 2025 targets 8% ex-COVID revenue growth and higher EBITDA margin, while China remains a headwind and U.S. market outlook is robust.
DiaSorin Earnings Call Transcript: Q3 2024
Q3 saw double-digit ex-COVID growth, with strong immuno and molecular performance, especially in the U.S. and Europe. Guidance for 2024 was raised, with continued challenges in China and LTG instrument sales, but robust cash flow and margin improvement support a positive outlook.
Diagnostics group DiaSorin's nine-month adjusted core profit up 6%
Italian medical diagnostics group DiaSorin on Tuesday posted a 6% jump in nine-month adjusted core profit to 292 million euros ($318.46 million) at constant exchange rates, driven by its immunodiagnos...
DiaSorin Earnings Call Transcript: Q2 2024
Q2 2024 delivered strong ex-COVID growth, led by immunoassay and molecular diagnostics, with robust US and European performance. Guidance for 2024 was raised, expecting 6–7% ex-COVID revenue growth and a 33% EBITDA margin, while new platforms like LIAISON Plex are gaining traction.
DiaSorin Earnings Call Transcript: Q1 2024
Diasorin 2023 revenue drops 14%, in line with guidance; shares fall
Italian medical diagnostic group Diasorin on Friday reported a double-digit drop in revenue for 2023, in line with its revenue guidance for the year, but shares dropped as much as 7.3%.